Biologic drugs account for over 40 percent of U.S. prescription drug spending despite treating only about 2 percent of patients. If you have ever wondered what are biosimilars and why they matter for your wallet, the answer starts with understanding how competition drives down the cost of these complex, life-changing therapies. Since the first U.S. biosimilar approval in 2015, these products have already saved the healthcare system billions of dollars.
Defining Biosimilars
A biosimilar is a biologic product that is highly similar to an already approved biologic medicine, known as the reference product. The FDA defines a biosimilar as having no clinically meaningful differences from the reference product in terms of safety, purity, and potency. This standard was established under the Biologics Price Competition and Innovation Act (BPCIA), signed into law in 2010 as part of the Affordable Care Act.
Understanding what are biosimilars requires recognizing that biologic drugs are manufactured using living cells, which makes them fundamentally different from traditional small-molecule medications. Biologics include monoclonal antibodies, fusion proteins, and other large, complex molecules that cannot be replicated exactly through chemical synthesis. This complexity is precisely why biosimilars follow a distinct regulatory pathway from generic drugs.
How Biosimilars Are Made
Biosimilar manufacturers begin by reverse-engineering the reference biologic’s molecular structure using advanced analytical techniques. They develop their own cell lines and manufacturing processes to produce a product that matches the reference as closely as possible. Because living cells are involved, minor differences in protein folding, glycosylation patterns, and other post-translational modifications are expected and acceptable, provided they do not affect clinical performance.
The manufacturing process is extensive and capital-intensive. A single biosimilar manufacturing facility can cost $200 million or more to build, and development timelines typically span 7 to 10 years from initial research to FDA approval. Despite these costs, biosimilars are significantly cheaper to bring to market than novel biologics, which often require over $1 billion in total development investment.
The FDA Approval Process for Biosimilars
The FDA’s biosimilar approval pathway, codified under Section 351(k) of the Public Health Service Act, requires a stepwise demonstration of biosimilarity. Manufacturers must submit comprehensive analytical data comparing the biosimilar to the reference product, followed by animal studies and at least one clinical study in a relevant patient population.
Clinical trials for biosimilars are designed differently from those of novel drugs. Rather than proving absolute efficacy, biosimilar trials aim to demonstrate equivalence with the reference product. This typically involves randomized, double-blind studies comparing clinical response rates, pharmacokinetics, and immunogenicity between the biosimilar and the reference.
As of early 2026, the FDA has approved over 45 biosimilar products referencing more than 20 distinct biologic drugs. Notable approvals include biosimilars for adalimumab (Humira), infliximab (Remicade), trastuzumab (Herceptin), and bevacizumab (Avastin). The pace of approvals has accelerated in recent years, reflecting both regulatory experience and growing manufacturer investment in this space.
How Biosimilars Save You Money
Biosimilars reduce costs through market competition, much like generic drugs do for small-molecule medications. However, the savings dynamics differ. While generic drugs typically achieve price reductions of 80 to 90 percent, biosimilars generally offer savings of 15 to 40 percent initially, with deeper discounts emerging as more competitors enter the market.
The IQVIA Institute reported that biosimilars saved the U.S. healthcare system approximately $23.5 billion between 2015 and 2023. These savings come from both direct price reductions and competitive pressure that forces reference product manufacturers to lower their own prices. For individual patients, switching to a biosimilar can reduce out-of-pocket costs by hundreds to thousands of dollars per year.
Your actual savings depend on several factors, including your insurance plan, the specific biosimilar product, and pharmacy pricing. Many insurers have begun placing biosimilars on preferred formulary tiers to encourage adoption and maximize cost savings. Resources like GoodRx can help you compare prices and find the best deal at your local pharmacy.
Biosimilars vs Generics: Key Distinctions
One of the most common misconceptions is that biosimilars are simply “generic biologics.” While the concept is similar, the regulatory, manufacturing, and clinical realities are meaningfully different. Generic drugs are chemically identical to their reference products, while biosimilars are highly similar but not identical due to the inherent variability of biological manufacturing.
This distinction affects everything from the approval pathway to pharmacy substitution rules. For a thorough comparison, see our article on biosimilar vs generic differences. The bottom line is that both biosimilars and generics serve the same fundamental purpose of introducing competition to reduce drug prices, but they do so through different mechanisms and regulatory frameworks.
Safety and Efficacy Track Record
Biosimilars have accumulated a strong safety and efficacy record over more than a decade of clinical use. The European Medicines Agency approved the first biosimilar in 2006, providing nearly 20 years of real-world evidence supporting their safety. In the United States, post-market surveillance data have not identified any meaningful safety differences between approved biosimilars and their reference products.
Major medical organizations including the American Medical Association, the National Comprehensive Cancer Network, and the American College of Rheumatology have issued statements supporting biosimilar use. These endorsements reflect confidence in the FDA’s rigorous approval standards and the growing body of evidence from clinical practice.
Switching studies, which evaluate patients who transition from a reference biologic to a biosimilar, have consistently demonstrated that switching does not increase the risk of adverse events or reduce treatment effectiveness. This evidence is critical for patients who may be concerned about changing from a familiar medication to a newer alternative.
Interchangeability: What It Means for You
An interchangeable biosimilar meets an additional regulatory standard beyond basic biosimilarity. The FDA grants interchangeability designations to biosimilars that demonstrate they can be substituted for the reference product at the pharmacy level without the prescriber’s direct involvement, similar to how generic drugs are substituted for brand-name medications.
To earn interchangeability status, manufacturers must conduct switching studies showing that patients who alternate between the biosimilar and the reference product do not experience increased risks compared to those who remain on the reference product continuously. Several biosimilars have achieved this designation, and more are expected in the coming years.
Frequently Asked Questions
Are biosimilars safe to use?
Yes. The FDA requires extensive testing before approving any biosimilar, including analytical comparisons, animal studies, and clinical trials. Post-market surveillance over more than a decade has confirmed that approved biosimilars have safety profiles comparable to their reference products. Major medical organizations worldwide endorse their use.
How much cheaper are biosimilars than biologics?
Biosimilars typically launch at prices 15 to 40 percent lower than the reference biologic, with discounts increasing as more competitors enter the market. In some categories, such as biosimilar Humira alternatives, competition has driven prices down by 80 percent or more. Your actual savings depend on insurance coverage and pharmacy pricing.
Can my doctor switch me to a biosimilar?
Yes. Your doctor can prescribe a biosimilar at any time if they determine it is appropriate for your treatment. If the biosimilar has an interchangeability designation, your pharmacist may also be able to make the switch without a new prescription, depending on state law. Always discuss any medication changes with your healthcare provider.
Why don’t more people use biosimilars?
Adoption has been slower than expected for several reasons, including patent litigation delays, rebate structures that favor reference products, lack of physician and patient awareness, and formulary decisions by pharmacy benefit managers. However, adoption rates are increasing as more products reach the market and payers implement policies encouraging biosimilar use.
Making Biosimilars Work for Your Budget
Now that you understand what are biosimilars and how they function, the practical next step is to explore whether a biosimilar option exists for any biologic medication you currently take. Ask your physician about available alternatives, check with your insurance provider about formulary coverage, and compare prices using pharmacy discount tools. Biosimilars represent one of the most significant opportunities to reduce healthcare costs without compromising treatment quality, and staying informed is the first step toward capturing those savings.